跳至主要内容
临床试验/NCT05766176
NCT05766176已完成不适用

Study of the Effectiveness of The COVID-19 Vaccine

Universitas Sebelas Maret1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
1
主要终点
quantitative anti-sars-cov-2 titers

研究概览

简要总结

This descriptive study examines neutralizing antibody levels against COVID-19 in health workers before and after the 2nd booster of the COVID-19 vaccine in Surakarta, Indonesia.

详细描述

This research is a cross-sectional study with a descriptive-analytic design, community-based, of adults who live in Surakarta (age 18 years and over) using the Google form. The inclusion criteria were health workers receiving the third or second dose of the COVID-19 vaccine. Quantitative antibody titers are checked at Prodia's laboratory. Other variables examined were the number and date of vaccination, age, sex, comorbid diseases, body mass index, AEFI symptoms after the vaccine, and history of being infected with COVID-19. In the statistical analysis using the different and regression correlation tests, the significance level of P is less than 0.05.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Health workers who receive the second booster of COVID-19 vaccination

排除标准

  • Pregnancy

结局指标

主要结局

quantitative anti-sars-cov-2 titers

时间窗: Change of quantitative anti-sars-cov-2 titers before the second booster of vaccination COVID-19 and one month after

The quantitative Anti-SARS-CoV-2 test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein (S) which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nurhasan Agung Prabowo

Head of Hospital Research Unit

Universitas Sebelas Maret

研究点 (1)

Loading locations...

相似试验